Skip to content

Price Control of Publicly Financed Medicinal Products – The Slovenian Example

Marcel Hajd


Over the last few decades, the pharmaceutical industry has been subject to stricter regulation in relation to patents, testing, safety, efficiency and marketing, and, more recently, price control. In a global context, Slovenia is regarded as a high-income country, but with a population of only 2 million, its pharmaceutical market is small. Yet the Slovenian pharmaceutical industry is a conventionally well-developed and long-standing sector with a focus on international markets. While pharmaceutical consumption is rising globally, high-income countries remain the major market for the pharmaceutical industry. Since the positive aim of price control is, or at least should be, ensuring wide access to health treatment, such price regulation may reduce investment in medicinal products discovery, thereby curtailing innovation. This paper analyses the current pricing and reimbursement system of medicinal products in Slovenia, while considering public resources along with the impact on pricing systems of other countries which reference Slovenia.

Marcel Hajd (esq.), Legal Counsel at Marifarm d.o.o. (Slovenia). For Correspondence: <>


Lx-Number Search

(e.g. A | 000123 | 01)

Export Citation